Cilnidipine Market By Treatment (High Blood Pressure (Hypertension), Prevent Heart Attacks and Strokes, Prevent Angina (Heart-Related Chest Pain), Decrease Protein Leakage from the Kidney in Patients who Have Diabetes, Others); By Doses (10mg Tablet, Combination Doses); By Region (China, Japan, Korea, India, Europe) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 - 2029
Industry Trends
The prevalence of illnesses as a result of urbanization, and the rising competition in workplace, is a global phenomena. Several countries reported a rise in cases of hypertension, and heart related illness in the last 20 years, predominantly due to the changes in lifestyle amongst individuals. Higher competition in the workplace which is leading to a deterioration of health condition, and increased pressure amongst students is a serious concern amongst government health bodies, especially in the APAC region. The treatment of hypertension is made possible by the use of Cilnidipine, which is essentially a calcium channel blocker. It is accompanied with both L-type and N-type calcium channel blocking capabilities. The drug was developed by Fuji Viscera Pharmaceutical Company, and Ajinomoto, which are companies based in Japan. Cilnidipine was approved for use as a medicine in 1995, after it was patented in 1984. Apart from hypertension, Cilnidipine has also been proven to reduce blood pressure, decrease protein leakage from kidney, angina, amongst others. Cilnidipine helps in the dilation of arterioles and venules, thereby reducing the pressure in the capillary bed due to its blocking action at both N-type and L-type calcium channels. Cilnidipine presents a rapid absorption, and the concentration peak is generally observed after two hours. The distribution is higher in the kidney, as well as the liver. But, Cilnidipine has been reported to present low bioavailability, which is observed to be approximately 13%. The drug is metabolised quickly by both the liver and the kidney. In the liver, it is metabolized at a faster pace due to the presence of microsomes through the process of hydrogenation. Cilnidipine containing drugs are also available at economical rates, especially in countries like India and China. In India, for instance, Cilacar, a drug that contains cilnidipine, which is manufactured by J B Chemicals and Pharmaceuticals Ltd, is available for US$ 0.12 per tablet. The global cilnidipine market is seeing considerable growth due to the rising demand for efficient management of hypertension, especially amongst the geriatric population.
The use of cilnidipine in patients is associated with several side effects such as feet swelling, tiredness, headache, nausea, depression, stomach pain and male sexual dysfunction, amongst others. In rare cases, abnormal functioning of the liver is also observed. The drug is not advised for patients who have suffered a recent heart attack, have low blood pressure due to various heart conditions, etc. Increasing efficiency of cilnidipine drugs, and management of the aforementioned side effects with the help of technology will lead to the further adoption of cilnidipine drugs, thereby leading to the growth of the global cilnidipine market.
The COVID-19 pandemic has taken the world by storms. The mutation of coronavirus is presenting additional challenges to government bodies, and lockdown measures are being mulled over in several countries. Businesses have also taken a serious hit due to the COVID-19 pandemic. Healthcare bodies are working overtime to ensure safe treatment of individuals who have been affected by the coronavirus. Home-based treatment of non-serious illnesses has seen a significant spike in the last 12 months, as individuals are increasingly choosing to avoid hospitals due to the threat of COVID-19 spread. Loss in revenue has resulted in massive lay-offs and salary cut by various companies, and this has lead to a rise in stress in numerous individuals. The ability of the cilnidipine drug in managing hypertension is expected to drive its adoption amongst individuals who have fallen victim to hypertension and stress caused due to both social and professional anxiety during the pandemic. Therefore, the COVID-19 pandemic is expected to have a positive impact on the global cilnidipine market in the coming years.
In terms of revenue, the global cilnidipine market was valued at US$ 9802.50 Mn in 2020 and is expected to reach US$ 48552.98 Mn by 2029, growing at a CAGR of 19.52% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions.
Treatment Outlook:
Based on the use of cilnidipine or treatment type, high blood pressure (hypertension) accounted for the highest share in the global cilnidipine market in 2020, with a total market revenue of US$ 3274.93 Mn. Researchers believe that the upper and lower blood pressure level in hypertensive patients aged less than sixty should be below 140 mmHg and above 90 mmHg respectively. Treatment of hypertension can be achieved using angiotensin converting enzyme inhibitor (ACEI), calcium channel blocker (CCB), angiotensin receptor blocker (ARB), or diuretics. Cilnidipine is a class of CCB which is generally chosen as the first line of defence in the management of hypertension. It results in lesser damage to glomeruli, and also helps in the suppression of podocyte injury. Cilnidipine has the ability to raise insulin sensitivity. Hence, Cilnidipine is an ideal candidate for the treatment of hypertensive patients that also have conditions such as diabetes and chronic kidney illnesses. These factors have resulted in the higher share of hypertension segment in the global cilnidipine market. However, the prevention of heart attacks and strokes in individuals is expected to show the highest growth during the forecast years in the global cilnidipine market, with an expected CAGR of 20.14% over the forecast period.
Region Outlook:
The use of cilnidipine isn't approved in all regions. Based on the regions, the global cilnidipine market consists of Europe, China, Japan, India and South Korea. In 2020, Europe accounted for the highest share in the global cilnidipine market. The easier availability of cilnidipine in the European Union, coupled with the higher awareness regarding the use of the product for curing conditions such as hypertension, heart attack and strokes, etc., is a major reason for the higher share of Europe in the global cilnidipine market. Furthermore, the regions also has the presence of a number of cilnidipine-based drugs, which helps in increasing the accessibility of these products amongst individuals. However, India is expected to show the highest growth during the forecast years in the global cilnidipine market, with an expected CAGR of 20.21%. The rise in consumption of cilnidipine drug which is facilitated by the higher investment in primary and secondary healthcare in the country, coupled with government initiatives to promote accessibility of drugs to treat the growth in hypertension, especially amongst the young adults, is expected to the increase the market share of India in the global cilnidipine market. Studies show that around 11% of individuals aged between 15 and 49 were affected by hypertension. Country-wise, China accounted for the largest revenue share in 2020. The country is seeing a rise in domestic companies that are providing cilnidipine for medicine manufacture. The growth of online sales channels such as Alibaba is also facilitating the easier distribution of cilnidipine, thereby aiding the growth of the cilnidipine market in China.
Global Cilnidipine Market Revenue & Forecast, (US$ Million), 2015 – 2029
Competitive Landscape
The report provides both, qualitative and quantitative research of cilnidipine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the cilnidipine market are Abbott, Ajanta Pharma Ltd, Alembic Pharmaceuticals Ltd, Alkem Laboratories Ltd, Eris Lifesciences Ltd, Fuji Viscera Pharmaceutical Company and Ajinomoto Intas Pharmaceuticals Ltd, J B Chemicals and Pharmaceuticals Ltd, Lupin Ltd, Macleods Pharmaceuticals Pvt Ltd, Mankind Pharma Ltd, Medley Pharmaceuticals, Micro Labs Ltd, Niksan Pharmaceutical, Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Trumac Healthcare, ZydusCadila, amongst others.
Global Cilnidipine Market:
- By Treatment
- High Blood Pressure (Hypertension)
- Prevent Heart Attacks and Strokes
- Prevent Angina (Heart-Related Chest Pain)
- Decrease Protein Leakage from the Kidney in Patients who Have Diabetes
- Others
- By Doses
- 10mg Tablet
- Combination Doses
- By Region
- China
- Japan
- Korea
- Europe
- India
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Cilnidipine Market
6. Market
Synopsis: Cilnidipine Market
7. Cilnidipine
Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Cilnidipine
Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Cilnidipine Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
COVID-19 on Global Cilnidipine Market
8. Global
Cilnidipine Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Cilnidipine Market Revenue (US$ Mn)
8.2. Global
Cilnidipine Market Revenue (US$ Mn) and
Forecasts, By Treatment
8.2.1. High
Blood Pressure (Hypertension)
8.2.1.1. Definition
8.2.1.2. Market
Penetration, 2019
8.2.1.3. Market
Estimation, 2015 – 2020
8.2.1.4. Market
Forecast, 2021 – 2029
8.2.1.5. Compound
Annual Growth Rate (CAGR)
8.2.1.6. Regional
Bifurcation
8.2.1.6.1. China
8.2.1.6.1.1. Market
Estimation, 2015 – 2020
8.2.1.6.1.2. Market
Forecast, 2021 – 2029
8.2.1.6.2. Japan
8.2.1.6.2.1. Market
Estimation, 2015 – 2020
8.2.1.6.2.2. Market
Forecast, 2021 – 2029
8.2.1.6.3. South
Korea
8.2.1.6.3.1. Market
Estimation, 2015 – 2020
8.2.1.6.3.2. Market
Forecast, 2021 – 2029
8.2.1.6.4. India
8.2.1.6.4.1. Market
Estimation, 2015 – 2020
8.2.1.6.4.2. Market
Forecast, 2021 – 2029
8.2.1.6.5. Europe
8.2.1.6.5.1. Market
Estimation, 2015 – 2020
8.2.1.6.5.2. Market
Forecast, 2021 – 2029
8.2.2. Prevent
Heart Attacks and Strokes
8.2.2.1. Definition
8.2.2.2. Market
Penetration, 2019
8.2.2.3. Market
Estimation, 2015 – 2020
8.2.2.4. Market
Forecast, 2021 – 2029
8.2.2.5. Compound
Annual Growth Rate (CAGR)
8.2.2.6. Regional
Bifurcation
8.2.2.6.1. China
8.2.2.6.1.1. Market
Estimation, 2015 – 2020
8.2.2.6.1.2. Market
Forecast, 2021 – 2029
8.2.2.6.2. Japan
8.2.2.6.2.1. Market
Estimation, 2015 – 2020
8.2.2.6.2.2. Market
Forecast, 2021 – 2029
8.2.2.6.3. South
Korea
8.2.2.6.3.1. Market
Estimation, 2015 – 2020
8.2.2.6.3.2. Market
Forecast, 2021 – 2029
8.2.2.6.4. India
8.2.2.6.4.1. Market
Estimation, 2015 – 2020
8.2.2.6.4.2. Market
Forecast, 2021 – 2029
8.2.2.6.5. Europe
8.2.2.6.5.1. Market
Estimation, 2015 – 2020
8.2.2.6.5.2. Market
Forecast, 2021 – 2029
8.2.3. Prevent
Angina (Heart-Related Chest Pain)
8.2.3.1. Definition
8.2.3.2. Market
Penetration, 2019
8.2.3.3. Market
Estimation, 2015 – 2020
8.2.3.4. Market
Forecast, 2021 – 2029
8.2.3.5. Compound
Annual Growth Rate (CAGR)
8.2.3.6. Regional
Bifurcation
8.2.3.6.1. China
8.2.3.6.1.1. Market
Estimation, 2015 – 2020
8.2.3.6.1.2. Market
Forecast, 2021 – 2029
8.2.3.6.2. Japan
8.2.3.6.2.1. Market
Estimation, 2015 – 2020
8.2.3.6.2.2. Market
Forecast, 2021 – 2029
8.2.3.6.3. South
Korea
8.2.3.6.3.1. Market
Estimation, 2015 – 2020
8.2.3.6.3.2. Market
Forecast, 2021 – 2029
8.2.3.6.4. India
8.2.3.6.4.1. Market
Estimation, 2015 – 2020
8.2.3.6.4.2. Market
Forecast, 2021 – 2029
8.2.3.6.5. Europe
8.2.3.6.5.1. Market
Estimation, 2015 – 2020
8.2.3.6.5.2. Market
Forecast, 2021 – 2029
8.2.4. Decrease
Protein Leakage from the Kidney in Patients who Have Diabetes
8.2.4.1. Definition
8.2.4.2. Market
Penetration, 2019
8.2.4.3. Market
Estimation, 2015 – 2020
8.2.4.4. Market
Forecast, 2021 – 2029
8.2.4.5. Compound
Annual Growth Rate (CAGR)
8.2.4.6. Regional
Bifurcation
8.2.4.6.1. China
8.2.4.6.1.1. Market
Estimation, 2015 – 2020
8.2.4.6.1.2. Market
Forecast, 2021 – 2029
8.2.4.6.2. Japan
8.2.4.6.2.1. Market
Estimation, 2015 – 2020
8.2.4.6.2.2. Market
Forecast, 2021 – 2029
8.2.4.6.3. South
Korea
8.2.4.6.3.1. Market
Estimation, 2015 – 2020
8.2.4.6.3.2. Market
Forecast, 2021 – 2029
8.2.4.6.4. India
8.2.4.6.4.1. Market
Estimation, 2015 – 2020
8.2.4.6.4.2. Market
Forecast, 2021 – 2029
8.2.4.6.5. Europe
8.2.4.6.5.1. Market
Estimation, 2015 – 2020
8.2.4.6.5.2. Market
Forecast, 2021 – 2029
8.2.5. Others
8.2.5.1. Definition
8.2.5.2. Market
Penetration, 2019
8.2.5.3. Market
Estimation, 2015 – 2020
8.2.5.4. Market
Forecast, 2021 – 2029
8.2.5.5. Compound
Annual Growth Rate (CAGR)
8.2.5.6. Regional
Bifurcation
8.2.5.6.1. China
8.2.5.6.1.1. Market
Estimation, 2015 – 2020
8.2.5.6.1.2. Market
Forecast, 2021 – 2029
8.2.5.6.2. Japan
8.2.5.6.2.1. Market
Estimation, 2015 – 2020
8.2.5.6.2.2. Market
Forecast, 2021 – 2029
8.2.5.6.3. South
Korea
8.2.5.6.3.1. Market
Estimation, 2015 – 2020
8.2.5.6.3.2. Market
Forecast, 2021 – 2029
8.2.5.6.4. India
8.2.5.6.4.1. Market
Estimation, 2015 – 2020
8.2.5.6.4.2. Market
Forecast, 2021 – 2029
8.2.5.6.5. Europe
8.2.5.6.5.1. Market
Estimation, 2015 – 2020
8.2.5.6.5.2. Market
Forecast, 2021 – 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Treatment
9. Global
Cilnidipine Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global
Cilnidipine Market Revenue (US$ Mn) and
Forecasts, By Doses
9.2.1. 10mg
Tablet
9.2.1.1. Definition
9.2.1.2. Market
Penetration, 2019
9.2.1.3. Market
Estimation, 2015 – 2020
9.2.1.4. Market
Forecast, 2021 – 2029
9.2.1.5. Compound
Annual Growth Rate (CAGR)
9.2.1.6. Regional
Bifurcation
9.2.1.6.1. China
9.2.1.6.1.1. Market
Estimation, 2015 – 2020
9.2.1.6.1.2. Market
Forecast, 2021 – 2029
9.2.1.6.2. Japan
9.2.1.6.2.1. Market
Estimation, 2015 – 2020
9.2.1.6.2.2. Market
Forecast, 2021 – 2029
9.2.1.6.3. South
Korea
9.2.1.6.3.1. Market
Estimation, 2015 – 2020
9.2.1.6.3.2. Market
Forecast, 2021 – 2029
9.2.1.6.4. India
9.2.1.6.4.1. Market
Estimation, 2015 – 2020
9.2.1.6.4.2. Market
Forecast, 2021 – 2029
9.2.1.6.5. Europe
9.2.1.6.5.1. Market
Estimation, 2015 – 2020
9.2.1.6.5.2. Market
Forecast, 2021 – 2029
9.2.2. Combination
Doses
9.2.2.1. Definition
9.2.2.2. Market
Penetration, 2019
9.2.2.3. Market
Estimation, 2015 – 2020
9.2.2.4. Market
Forecast, 2021 – 2029
9.2.2.5. Compound
Annual Growth Rate (CAGR)
9.2.2.6. Regional
Bifurcation
9.2.2.6.1. China
9.2.2.6.1.1. Market
Estimation, 2015 – 2020
9.2.2.6.1.2. Market
Forecast, 2021 – 2029
9.2.2.6.2. Japan
9.2.2.6.2.1. Market
Estimation, 2015 – 2020
9.2.2.6.2.2. Market
Forecast, 2021 – 2029
9.2.2.6.3. South
Korea
9.2.2.6.3.1. Market
Estimation, 2015 – 2020
9.2.2.6.3.2. Market
Forecast, 2021 – 2029
9.2.2.6.4. India
9.2.2.6.4.1. Market
Estimation, 2015 – 2020
9.2.2.6.4.2. Market
Forecast, 2021 – 2029
9.2.2.6.5. Europe
9.2.2.6.5.1. Market
Estimation, 2015 – 2020
9.2.2.6.5.2. Market
Forecast, 2021 – 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By Doses
10. Global
Cilnidipine Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Cilnidipine Market Revenue (US$ Mn) and Forecasts By Region
10.2.1. China
10.2.1.1. China
Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Treatment
10.2.1.1.1. High
Blood Pressure (Hypertension)
10.2.1.1.2. Prevent
Heart Attacks and Strokes
10.2.1.1.3. Prevent
Angina (Heart-Related Chest Pain)
10.2.1.1.4. Decrease
Protein Leakage from the Kidney in Patients who Have Diabetes
10.2.1.1.5. Others
10.2.1.2. China
Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Doses
10.2.1.2.1. 10mg
Tablet
10.2.1.2.2. Combination
Doses
10.2.2. Japan
10.2.2.1. Japan
Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Treatment
10.2.2.1.1. High
Blood Pressure (Hypertension)
10.2.2.1.2. Prevent
Heart Attacks and Strokes
10.2.2.1.3. Prevent
Angina (Heart-Related Chest Pain)
10.2.2.1.4. Decrease
Protein Leakage from the Kidney in Patients who Have Diabetes
10.2.2.1.5. Others
10.2.2.2. Japan
Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Doses
10.2.2.2.1. 10mg
Tablet
10.2.2.2.2. Combination
Doses
10.2.3. South
Korea
10.2.3.1. South
Korea Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Treatment
10.2.3.1.1. High
Blood Pressure (Hypertension)
10.2.3.1.2. Prevent
Heart Attacks and Strokes
10.2.3.1.3. Prevent
Angina (Heart-Related Chest Pain)
10.2.3.1.4. Decrease
Protein Leakage from the Kidney in Patients who Have Diabetes
10.2.3.1.5. Others
10.2.3.2. South
Korea Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Doses
10.2.3.2.1. 10mg
Tablet
10.2.3.2.2. Combination
Doses
10.2.4. India
10.2.4.1. India
Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Treatment
10.2.4.1.1. High
Blood Pressure (Hypertension)
10.2.4.1.2. Prevent
Heart Attacks and Strokes
10.2.4.1.3. Prevent
Angina (Heart-Related Chest Pain)
10.2.4.1.4. Decrease
Protein Leakage from the Kidney in Patients who Have Diabetes
10.2.4.1.5. Others
10.2.4.2. India
Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Doses
10.2.4.2.1. 10mg
Tablet
10.2.4.2.2. Combination
Doses
10.2.5. Europe
10.2.5.1. Europe
Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Treatment
10.2.5.1.1. High
Blood Pressure (Hypertension)
10.2.5.1.2. Prevent
Heart Attacks and Strokes
10.2.5.1.3. Prevent
Angina (Heart-Related Chest Pain)
10.2.5.1.4. Decrease
Protein Leakage from the Kidney in Patients who Have Diabetes
10.2.5.1.5. Others
10.2.5.2. Europe
Cilnidipine Market Revenue (US$ Mn) and Forecasts, By Doses
10.2.5.2.1. 10mg
Tablet
10.2.5.2.2. Combination Doses
10.3. Key
Segment for Channeling Investments
10.3.1. By Region
11. Competitive
Benchmarking
11.1. Market
Share Analysis, 2019
11.2. Global
Presence and Growth Strategies
11.2.1. Mergers
and Acquisitions
11.2.2. Product
Launches
11.2.3. Investments
Trends
11.2.4. R&D
Initiatives
12. Player
Profiles
12.1. Abbott
12.1.1. Company
Details
12.1.2. Company
Overview
12.1.3. Product
Offerings
12.1.4. Key Developments
12.1.5. Financial
Analysis
12.1.6. SWOT
Analysis
12.1.7. Business
Strategies
12.2. Ajanta
Pharma Ltd
12.2.1. Company
Details
12.2.2. Company
Overview
12.2.3. Product
Offerings
12.2.4. Key
Developments
12.2.5. Financial
Analysis
12.2.6. SWOT
Analysis
12.2.7. Business
Strategies
12.3. Alembic
Pharmaceuticals Ltd
12.3.1. Company
Details
12.3.2. Company
Overview
12.3.3. Product
Offerings
12.3.4. Key
Developments
12.3.5. Financial
Analysis
12.3.6. SWOT
Analysis
12.3.7. Business
Strategies
12.4. Alkem
Laboratories Ltd
12.4.1. Company
Details
12.4.2. Company
Overview
12.4.3. Product
Offerings
12.4.4. Key
Developments
12.4.5. Financial
Analysis
12.4.6. SWOT
Analysis
12.4.7. Business
Strategies
12.5. Eris
Lifesciences Ltd
12.5.1. Company
Details
12.5.2. Company
Overview
12.5.3. Product
Offerings
12.5.4. Key
Developments
12.5.5. Financial
Analysis
12.5.6. SWOT
Analysis
12.5.7. Business
Strategies
12.6. Fuji
Viscera Pharmaceutical Company and Ajinomoto
12.6.1. Company
Details
12.6.2. Company
Overview
12.6.3. Product
Offerings
12.6.4. Key
Developments
12.6.5. Financial
Analysis
12.6.6. SWOT
Analysis
12.6.7. Business
Strategies
12.7. Intas
Pharmaceuticals Ltd
12.7.1. Company
Details
12.7.2. Company
Overview
12.7.3. Product
Offerings
12.7.4. Key
Developments
12.7.5. Financial
Analysis
12.7.6. SWOT
Analysis
12.7.7. Business
Strategies
12.8. J B
Chemicals and Pharmaceuticals Ltd
12.8.1. Company
Details
12.8.2. Company
Overview
12.8.3. Product
Offerings
12.8.4. Key
Developments
12.8.5. Financial
Analysis
12.8.6. SWOT
Analysis
12.8.7. Business
Strategies
12.9. Lupin Ltd
12.9.1. Company
Details
12.9.2. Company
Overview
12.9.3. Product
Offerings
12.9.4. Key
Developments
12.9.5. Financial
Analysis
12.9.6. SWOT
Analysis
12.9.7. Business
Strategies
12.10. Macleods
Pharmaceuticals Pvt Ltd
12.10.1. Company
Details
12.10.2. Company
Overview
12.10.3. Product
Offerings
12.10.4. Key
Developments
12.10.5. Financial
Analysis
12.10.6. SWOT
Analysis
12.10.7. Business
Strategies
12.11. Mankind
Pharma Ltd
12.11.1. Company
Details
12.11.2. Company
Overview
12.11.3. Product
Offerings
12.11.4. Key
Developments
12.11.5. Financial
Analysis
12.11.6. SWOT
Analysis
12.11.7. Business
Strategies
12.12. Medley
Pharmaceuticals
12.12.1. Company
Details
12.12.2. Company
Overview
12.12.3. Product
Offerings
12.12.4. Key
Developments
12.12.5. Financial
Analysis
12.12.6. SWOT
Analysis
12.12.7. Business
Strategies
12.13. Micro
Labs Ltd
12.13.1. Company
Details
12.13.2. Company
Overview
12.13.3. Product
Offerings
12.13.4. Key
Developments
12.13.5. Financial
Analysis
12.13.6. SWOT
Analysis
12.13.7. Business
Strategies
12.14. Niksan
Pharmaceutical
12.14.1. Company
Details
12.14.2. Company
Overview
12.14.3. Product
Offerings
12.14.4. Key
Developments
12.14.5. Financial
Analysis
12.14.6. SWOT
Analysis
12.14.7. Business
Strategies
12.15. Sun
Pharmaceutical Industries Ltd
12.15.1. Company
Details
12.15.2. Company
Overview
12.15.3. Product
Offerings
12.15.4. Key
Developments
12.15.5. Financial
Analysis
12.15.6. SWOT
Analysis
12.15.7. Business
Strategies
12.16. Torrent
Pharmaceuticals Ltd
12.16.1. Company
Details
12.16.2. Company
Overview
12.16.3. Product
Offerings
12.16.4. Key
Developments
12.16.5. Financial
Analysis
12.16.6. SWOT
Analysis
12.16.7. Business
Strategies
12.17. Trumac
Healthcare
12.17.1. Company
Details
12.17.2. Company
Overview
12.17.3. Product
Offerings
12.17.4. Key
Developments
12.17.5. Financial
Analysis
12.17.6. SWOT
Analysis
12.17.7. Business
Strategies
12.18. Zydus
Cadila
12.18.1. Company
Details
12.18.2. Company
Overview
12.18.3. Product
Offerings
12.18.4. Key
Developments
12.18.5. Financial
Analysis
12.18.6. SWOT
Analysis
12.18.7. Business
Strategies
12.19. Other
Market Participants
13. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
